Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Reynolds

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
North American Spine Society Journal|June 2, 2023
Publication rates of abstracts presented across 6 major spine specialty conferencesTariq Z Issa, Yunsoo Lee, Mark J Lambrechts, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 30, 2005
Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host diseaseJoseph P Uberti, Lois Ayash, Voravit Ratanatharathorn, et al.
The Lancet. Oncology|November 25, 2017
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 studyRoy S Herbst, Mary W Redman, Edward S Kim, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
North American Spine Society Journal|June 2, 2023
Publication rates of abstracts presented across 6 major spine specialty conferencesTariq Z Issa, Yunsoo Lee, Mark J Lambrechts, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 30, 2005
Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host diseaseJoseph P Uberti, Lois Ayash, Voravit Ratanatharathorn, et al.
The Lancet. Oncology|November 25, 2017
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 studyRoy S Herbst, Mary W Redman, Edward S Kim, et al.
Pageof 4